Valicenti Advisory Services Inc. Sells 125 Shares of Becton, Dickinson and Company (NYSE:BDX)

Valicenti Advisory Services Inc. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,475 shares of the medical instruments supplier’s stock after selling 125 shares during the period. Valicenti Advisory Services Inc.’s holdings in Becton, Dickinson and Company were worth $356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. WR Wealth Planners LLC grew its holdings in Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares in the last quarter. Clear Creek Financial Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares in the last quarter. Central Pacific Bank Trust Division boosted its holdings in shares of Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares in the last quarter. Finally, Capital Advisors Ltd. LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 48 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

BDX opened at $238.62 on Friday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $68.96 billion, a PE ratio of 52.56, a P/E/G ratio of 1.79 and a beta of 0.42. The firm has a 50 day moving average of $237.33 and a two-hundred day moving average of $235.16.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same period last year, the firm posted $2.96 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent analyst reports. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and an average price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.